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Background: The objective of this retrospective analysis is to systematically assess osseous lesions on the basis of a
validated scoring system in terms of stability and fractures prior to and following radiotherapy in 338 lung cancer
patients with bone metastases in the vertebral column.
Methods: The stability of 338 patients with 981 osteolytic metastases in the thoracic and lumbar spine was
evaluated retrospectively on the basis of the Taneichi-Score between January 2000 and January 2012.
Results: 64% (215 patients) were classified stable prior to radiotherapy. Of the stable osseous metastases, none
were rated unstable in the further course (p < 0.001, McNemar test). Of the 123 patients in whom the metastases
were classified unstable prior to radiotherapy, 21 patients (17%) were classified stable after three months, and 30
patients (24%) stable after six months. A pathological fracture was diagnosed in 62 patients (18%) prior to
radiotherapy. Regarding cases of osteolytic metastases of the vertebral bodies in which no fractures could be
detected prior to the start of therapy, fractures occurred in 2% of all patients (n = 7) within six months following
radiotherapy.
Conclusions: Our analysis demonstrated that pathological fractures following radiotherapy occur in the very
minority of vertebral lesions for patients with a favorable outcome. The use of a systematic radiological scoring
system to classify osteolytic metastases of the vertebral column has shown to be feasible in daily routine.
Prospective clinical trials are warranted in order to analyse, to what extent patients with osseous metastases can be
mobilized by physiotherapy for strengthening the paravertebral muscles before radiotherapy effects can be
measured by means of radiological recalcification.
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Metastases of the bone occur in 30-36% of the patients
with lung cancer; 65% of these metastases are discovered
at the time of the initial staging [1,2]. The vertebral col-
umn is the principal localization of the osseous metasta-
ses and is in many cases an indication of an advanced
stage of a malignant primary disease [3,4].* Correspondence: harald.rief@med.uni-heidelberg.de
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reproduction in any medium, provided the orAdvanced lung cancer is diagnosed in over two thirds
of the patients, a figure that correlates with a high mor-
tality [5]. In the majority of patients in lung cancer with
bone metastases, the treatment of osteolytic metastases
in the daily clinical practice is common. The aim of ther-
apy here is to reduce pain, to improve the functionality,
and to prevent complications, for example compression
of the spinal cord and pathological fractures. The treat-
ment of osseous metastases is complex and requires a
multidisciplinary approach in the form of analgesic ther-
apy, systemic treatment, radiotherapy, and surgical inter-
ventions as measures to optimize the prospects of success
in the individual therapy of patients [6]. Metastases of the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




















Squamous cell carcinoma 40 12
Small cell carcinoma 35 10
Large cell carcinoma 8 2
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able of causing distinct symptoms of pain, bone fractures,
compression of the spinal cord, and hypercalcaemia, with
a significant reduction in the patients’ quality of life. Me-
tastases occur most frequently as osteolytic factors in con-
nection with bronchial carcinoma and have significant
effects on the stability of the vertebral column and the pa-
tients’ mobility.
Palliative radiotherapy represents one of the principal
therapeutical methods for patients with osseous metasta-
ses [4]. The most frequent indications for therapy are
the presence of pain, existing or impending instability,
neurological symptoms due to compression of the spinal
cord, or following surgical intervention [1]. An essential
aspect is the stability of the vertebral bodies affected. Pa-
tients with unstable osteolytic vertebral bodies are usu-
ally given an orthopedic thoracic corset to wear. The
pain that is already present is hence additionally
compounded by an impairment of mobility and subse-
quently a further reduction in the patients’ quality of
life.
The German Association for Sports Medicine and Pre-
vention and the German Cancer Society have published
guidelines for the design of training and sports programs
for tumor patients; in these guidelines, the targeted
sports intervention is deemed contraindicated in patients
with osseous metastases [7]. A systematic classification
regarding the stability of the metastases in the vertebral
bodies has so far been carried out in only relatively few
clinics. The use of a validated scoring system to assess
the stability of osseous metastases in the vertebral col-
umn may produce early mobilization in palliative-stage
patients. The objective of this retrospective analysis is to
systematically assess the osseous lesions in terms of sta-
bility and fractures prior to and following radiotherapy
in bronchial-carcinoma patients with bone metastases.
Methods
Of a total population of 963 patients whose osseous le-
sions were treated by radiotherapy at the University
Clinic of Heidelberg for osteolytic metastases of the
vertebral column due to histologically diagnosed bron-
chial carcinoma in the period from January 2000 up to
January 2012, 338 patients exhibited a survival time
exceeding six months; these were examined using com-
puter tomography. This group of patients was screened in
this retrospective analysis. Inclusion criteria for the further
investigation were radiotherapy performed in the seg-
ments afflicted, osteolytic metastases, localization in the
thoracic and lumbar spine, and a minimum duration of
follow-up treatment of six months. Accordingly 338 pa-
tients presenting 981 osseous lesions in the thoracic and
lumbar spine were evaluated. Many patients exhibited
more than one treated lesion; only one lesion per vertebralbody was included in the analysis. The patient data were
taken from the Heidelberg NCT Cancer Register. This
study was given the positive vote of approval of the
Heidelberg Ethics Committee on 22 October 2012.
The diagnosis of osseous metastasis was made on the
basis of the findings of computer tomography, magnetic-
resonance imaging, or bone-scintigraphy investigations.
The patient data are summarized in Table 1.
The mean age of the patients at the time of the
diagnosis of osseous metastasis was 64 years (range
41–88 years). 232 patients (69%) were male and 106
patients (31%) female. Adenocarcinoma was the most
frequently diagnosed histological subtype (75%). The
performance status was qualified on the basis of the
Karnofsky Index [8]. 146 patients (43%) had solitary
metastases, while in 192 patients (57%) multiple ver-
tebral bodies were affected.
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assessed according to the Taneichi score [9] on the basis
of the CT image recorded before radiotherapy to plan
treatment and also in the follow-up stage three and six
months after radiotherapy (Figure 1).
The osteolytic metastases were rated on a scale
from A to G. Subtypes A to C were defined as stable,
subtypes D to G as unstable. In cases in which only
one lesion was rated as unstable in a patient with
multiple metastases, the score was “unstable”. In 74%
of the patients (n = 249; 1–12) the thoracic spine was
involved, in 26% (n = 89; 1–12) the lumbar spine. 43%






Figure 1 Taneichi Score. The stability was assessed according to the TaneIn 90% of the cases (303 patients) the primary tumor
was an NSCLC, in 10% (35 patients) small-cell bronchial
carcinoma. 58% of all patients received chemotherapy
prior to their radiotherapy; 85% of the patients were
under treatment with bisphosphonates.
Radiotherapy
The most frequent indication for radiotherapy, in 62% of
all cases, was pain; further indications were instability
(32%), and neurological symptoms (4%). Radiotherapy
post- laminectomy surgery was applied in 2%.
Radiotherapy was carried out at the Department of
Radiation Oncology of the University Hospital Heidelberg.
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dorsal photon field with the energy 6 MV. PTV covered
the specific vertebral body affected as well as the ones im-
mediately above and below. 276 patients were treated with
10 × 3 Gy, 24 patients with 14 × 2.5 Gy, 25 patients with
20 × 2 Gy, and 13 patients with 1 × 8 Gy. The median indi-
vidual dose in all patients was 3 Gy, the median total dose
30 Gy. The respective individual and total doses were cal-
culated separately for each individual patient, depending
on the histology, the patient’s general state of health, and
the current staging and the respective prognosis (Table 2).
Statistical analysis
The empirical distribution of continuous variables is de-
scribed by the number of observations, mean and stand-
ard deviation; the description of categorical variables
includes the number and percentage of patients belong-
ing to the relevant categories. Bowker’s test and kappa
statistics were calculated to detect possible asymmetry
in the distribution of the Taneichi score [9] over time.
Graphical methods are applied to present the observed
data. Multivariable logistic regression analysis was
performed to evaluate possible predictors for stability
after six months.
Results
981 lesions in 338 patients were assessed according to
the Taneichi scoring system [9] both prior to radiother-
apy as well as three and six months post radiotherapy on
the basis of CT images. The median follow up of all pa-
tients was 9.3 months (mean 12.2, min. 0.4, max.Table 2 Treatment characteristics
Characteristics n %
Radiotherapy dose completed (Gy)
Single dose (median, range) 3 (1-4)






Treatment for primary site
Chemotherapy Yes 195 58
No 143 42
Other treatment for bone metastases
Orthopedic thoracic corset Yes 145 43
No 193 57
Bisphosphonates Yes 288 85
No 50 15130.1 month). The survival status at last follow-up
showed 26 patients (8%) still alive and 312 patients
(92%) death of disease. The most frequent subtype
according to Taneichi was subtype C, with 30%. The
mean number of metastases per patient was three
[1-12]. 64% (215 patients) were classified stable prior to
radiotherapy. Of the stable osseous metastases, none
were rated unstable in the further course (p < 0.001,
McNemar-test). Of the 123 patients in whom the metas-
tases were classified unstable prior to radiotherapy, 21
patients (17%) were classified stable after three months,
and 30 patients (24%) stable after six months. This
means that in total 70% and 74% of the osseous metasta-
ses were stable after three months and six months, re-
spectively (Table 3). Of the prognostic factors for a
therapeutic response already described in the literature
on several occasions, although the bisphosphonates did
not play a significant role regarding stability (p = 0.074,
odds ratio (OR) 1.6), they still appear to exert a positive
influence (Table 4). The same model was also used for
the aspect of fractures; here, however, no particular par-
ameter showed itself to be a prognostic factor. The
evaluation of the distribution of subtypes A to G
(Table 5) showed a major change in the direction of im-
provement over the course of time. Deterioration oc-
curred in 1.8% of the cases (n = 6), improvement in
19.3% (n = 63). No change was seen in 78.9% (n = 258) of
the cases. In patients with multiple metastases the most
negative subtype was rated, postoperative metastases
were not considered (n = 11). This test (Bowker test)
shows the distribution pattern of the subtypes according





Stability after 3 month
Unstable 102 30
Stable 236 70
Stability after 6 month
Unstable 93 28
Stable 245 72
Bone fracture before RT
Yes 62 18
No 276 82
Bone fracture 6 month after RT
Yes 69 20
No 269 80
Table 4 Results of prognostic factors related to stability
Parameter p-value Odds ratio 95% CI
Age 0.255 0.98 0.959-1.011
Karnofsky-index 0.867 0.99 0.976-1.021
Gender 0.109 1.52 0.909-2.560
Chemotherapy (yes vs. no) 0.692 0.83 0.334-2.074
Primary site (NSCLC vs SCLC) 0.118 0.53 0.246-1.171
Bisphosphonates (yes vs. no) 0.074 1.58 0.957-2.606
Number of metastasis (1 vs. > 1) 0.410 0.79 0.469-1.363
Multivariable regression analysis of prognostic factors related to stability.
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ation (kappa = 0.73) was good.
A pathological fracture was diagnosed in 62 patients
(18%) prior to radiotherapy. Regarding cases of osteolytic
metastases of the vertebral bodies in which no fracture
could be detected prior to the start of therapy, fractures
occurred in 2% of the patients (n = 7) within the six
months following radiotherapy. Of these 2% (n = 7) six
patients were unstable.
Discussion
An early identification of osseous metastases and their
classification in terms of stability is a major factor in the
decision for the therapeutical measures to be taken. The
scoring system according to Taneichi [9] constitutes a
simple method for classifying the vertebral bodies as
“stable” or “unstable”, which is why this score is
employed in this evaluation.
Osseous metastases in the vertebral bodies are a fre-
quent secondary disease associated with bronchial car-
cinoma. Palliative percutaneous radiotherapy represents
one of the most important measures in this context.
Symptoms such as painful mobility impairments, resting
pain, fear of pathological fractures, and fatigue result in
a substantial reduction in the patients’ quality of life onTable 5 The evaluation of the distribution of subtypes stabl
(0–6 month)










This Bowker Test showed the distribution of subtypes of Taneichi-Score before and
correlation (kappa = 0.73) was good. The evaluation of the distribution of subtypes
course of time. Deterioration occurred in 1.8% of the cases (n = 6), improvement inthe one hand; on the other, the treatment of this disease
requires protracted therapeutical measures that are
highly intensive in terms of cost and time. What is more,
some of the patients affected are at an acute risk of frac-
ture, with the potential risk of developing symptoms of
paraplegia.
The literature contains various classifications regard-
ing the stability of the vertebral column [9-12]. The es-
sential risk factors for instability comprise an excessive
tumor size, the localization of the tumor in the vertebral
body, the degree of stress on the vertebral bodies, bone
density, the destruction of the costovertebral articulation
and of the pedicles in the thoracolumbar spine, and the
type of tumor involved [13]. The study by Taneichi et al.
[9] defines the risk factors for fractures of the vertebral
bodies caused by osteolytic metastases and rates the esti-
mated fractures according to different types of meta-
static involvement, establishing criteria for assessing the
risk of vertebral-body fractures. The risk factors for
vertebral-body fractures in the thoracic region (T1-T10)
are the tumor size and the degree of destruction of the
costovertebral joint; in the thoracolumbar and lumbar
region (T10-L5), it is the tumor size and degree of ped-
icle destruction that are the main factors.
Our results show that the majority of the patients
(64%) already exhibit stable osseous metastases in the
vertebral column prior to the start of therapy. Radiother-
apy and consecutive resclerotization of the lesions made
it possible to reclassify 24% of the originally unstable
osteolytic processes as stable after six months. Consider-
ing all patients, this means that six months after radio-
therapy 72% of the patients can be classified stable. In
the literature, the therapeutic response is generally
expressed in terms of the quality of pain [14]. The assess-
ment of the therapeutic response using the Taneichi score
on the basis of changes in the subtypes has not been de-
scribed previously. The application of therapeutic measurese and instable metastases over the course of time
C D E F G Total
0 0 0 0 0 35
3 0 0 0 0 68
88 0 0 0 0 101
5 10 0 0 0 17
9 2 43 3 0 63
4 0 6 22 0 34
1 0 0 1 6 9
110 12 49 26 6 327
6 month after radiation therapy. Asymmetry was apparent (p = 0.0002) and the
A to G showed a major change in the direction of improvement over the
19.3% (n = 63). No change was seen in 78.9% (n = 258) of the cases.
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metastasis, producing an improvement in the Taneichi sub-
type to the next positive type up on the scale. This change
into a better subtype was seen in 19.3% of the lesions. This
result represents the therapeutic response of the osteolytic
lesions of a bronchial carcinoma following radiotherapy; it
is not, however, comparable with the clinical parameters
such as pain response.
Bisphosphonates were taken by 85% of the patients,
which is why they were not identified as a prognostic
factor in terms of stability. Chemotherapy, on the other
hand, showed a positive influence in terms of stability
and fractures.
The systematic review by Weber et al. [13] defined risk
factors regarding spinal instability caused by metastases.
Of these risk factors, only the number of metastases
showed a positive – albeit insignificant – effect in terms
of stability. A uniform classification of spinal metastases
in association with bronchial carcinoma has not yet been
described in the literature.
In previous retrospective studies among American and
Japanese populations, the incidence of pathologic frac-
tures in the vertebral column is given at 10% [1,15].
There are only few data available regarding the risk of
fractures of the vertebral bodies following radiotherapy.
Our results show a pathological fracture in 18% of the
vertebral bodies prior to radiotherapy. Other fractures
up to six months in the further course were seen in 2%
of all cases. In a further analysis by Saad et al. [16] the
risk of pathological fracture in association with lung can-
cer is given at 17%; this finding, however, was made rela-
tive to the entire skeletal system. Pathological fractures
are a frequently encountered event; fractures of the ver-
tebral body following radiotherapy, on the other hand
are seldom reported.
The vertebral column as the main axis of the human
body stands at the center of all the individual’s mobility fac-
ulties; when impaired, it constitutes a mobility-restricting
factor. Cheville et al. [17] in their study in patients with an
advanced tumor disease showed that radiotherapy can be
accompanied by physiotherapy, and that the adjunctive ef-
fect of this is beneficial. An active mobilization of these pa-
tients has so far been contraindicated according to the
recommendations of the German Association for Sports
Medicine and Prevention and the German Cancer Society
[7]. The strengthening of the paravertebral muscles could
be a reasonable therapeutical option for patients with
stable osseous lesions, and may produce an improvement
in their condition in terms of quality of life, fatigue, and
pain. Quality of life is an important factor in palliative-
stage patients with bronchial carcinoma, and is substan-
tially impaired by pain, fatigue, and loss of mobility. Seen
in this light, the classification of stability prior to the start
of therapy is of great importance.Only few clinics have established a uniform systematic
classification in terms of the stability of metastases in
the vertebral bodies. The high proportion of stable le-
sions and the negligibly small proportion of fractures
make this a potential new option in the palliative treat-
ment of osseous metastases of the vertebral column. The
feasibility of a dedicated sports program for these pa-
tients is currently the subject of a prospective study by
Rief et al. [18]. Our expectation is that the mobilization
of this hithertoin adequately considered category of pa-
tients will bring about a considerable improvement in
the quality of life of patients with osseous metastases
who have undergone radiotherapy. One factor that lim-
ited the expressiveness of this analysis, however, is the
fact that those patients with a survival time of less than
six months and other localizations of osseous metastases
were not considered. Usually, the benefit from RT re-
garding bone recalcification is observed after a minimum
of 3–6 months, so patients with a shorter survival will
not necessarily benefit from this radiotherapeutic effect,
and are thus excluded from analysis.
Conclusions
The use of a systematic radiological scoring system to
classify osteolytic metastases of the vertebral column has
shown itself to be practicable in the daily routine in the
radiology area. The next step that is planned is to use
the scoring system for other prospective studies in pa-
tients with radiologically treated osseous metastases to
validate the physiotherapeutical measures.
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